MNOV Earnings Date: Nov 12, 2026 (Estimated) — MediciNova, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MNOV's next earnings date?
MediciNova, Inc. (MNOV) is expected to report earnings on Thursday, November 12, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $50,000.
How did MNOV do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), MediciNova, Inc. posted EPS of -$0.05 versus the -$0.06 estimate, a beat of 16.7%. Revenue was $458,439 against a $75,000 estimate. The stock's 1-day post-earnings move was +0.0%.
How much does MNOV stock move after earnings?
MNOV beat EPS estimates in 7 of its last 7 reported quarters. Over the last 6 reports the stock moved an average of 2.1% (up or down) in the day after earnings.
About MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.06 | -0.05 | +16.67% | $458,439 | ✅ Beat | +0.00% | +4.58% | +42.75% |
| 2026-05-14 | Q1 2026 | -0.06 | -0.05 | +16.67% | $186,984 | ✅ Beat | -1.43% | -2.14% | -10.71% |
| 2026-02-20 | Q4 2025 | -0.08 | -0.05 | +37.50% | $151,739 | ✅ Beat | -0.67% | -3.33% | -3.33% |
| 2025-11-12 | Q3 2025 | -0.11 | -0.06 | +45.45% | $0 | ✅ Beat | -1.91% | -8.92% | -1.91% |
| 2024-11-13 | Q3 2024 | — | -0.06 | — | $0 | — | -8.75% | -2.50% | +5.00% |
| 2023-05-11 | Q1 2023 | -0.07 | -0.06 | +14.29% | $0 | ✅ Beat | +0.00% | -1.85% | +1.85% |
| 2022-11-10 | -0.09 | -0.07 | — | — | ✅ Beat | — | — | — | |
| 2022-08-11 | -0.09 | -0.08 | — | — | ✅ Beat | — | — | — |
Showing last 8 quarters.